← back to search

Brian MacKenna

Science Oxford · GB
Area of research
Infectious Diseases · Oncology
Research interest
Research interests include COVID-19 Clinical Research Studies, COVID-19 and healthcare impacts, SARS-CoV-2 and COVID-19 Research, and Long-Term Effects of COVID-19.
h-index
31
citations
12,806
works
248
NIH funding
primary concept
Medicine
email

Recent publications

A mixed methods protocol for an impact and implementation evaluation of the Pharmacy First Services for management of common conditions in England
International Journal of Pharmacy Practice 2025cited by 6position: middledoi
Healthcare use in individuals with rheumatoid arthritis during the COVID-19 pandemic and beyond: A cohort study in three nations of the UK
medRxiv 2025cited by 2position: middledoi
Impact of long COVID on health-related quality-of-life: an OpenSAFELY population cohort study using patient-reported outcome measures (OpenPROMPT)
The Lancet Regional Health - Europe 2024cited by 94position: middledoi
Healthcare utilisation in people with long COVID: an OpenSAFELY cohort study
BMC Medicine 2024cited by 29position: middledoi
Effectiveness of mRNA COVID-19 Vaccines as First Booster Doses in England: An Observational Study in OpenSAFELY-TPP
Epidemiology 2024cited by 7position: middledoi
Impact of COVID-19 on recorded blood pressure screening and hypertension management in England: an analysis of monthly changes in the quality and outcomes framework indicators in OpenSAFELY
Open Heart 2024cited by 5position: lastdoi
Identification of patients undergoing chronic kidney replacement therapy in primary and secondary care data: validation study based on OpenSAFELY and UK Renal Registry
BMJ Medicine 2024cited by 4position: middledoi
The safety of antivirals and neutralising monoclonal antibodies used in prehospital treatment of Covid-19
Journal of Infection 2024cited by 2position: middledoi
Changes in sick notes associated with COVID-19 from 2020 to 2022: a cohort study in 24 million primary care patients in OpenSAFELY-TPP
BMJ Open 2024cited by 2position: middledoi
Impacts of the COVID-19 pandemic on deprivation-level differences in cardiovascular hospitalisations: a comparison of England and Denmark using the OpenSAFELY platform and National Registry Data
BMJ Open 2024cited by 1position: middledoi
Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform
The Lancet Public Health 2023cited by 97position: middledoi
Comparative effectiveness of BNT162b2 versus mRNA-1273 covid-19 vaccine boosting in England: matched cohort study in OpenSAFELY-TPP
BMJ 2023cited by 41position: middledoi
Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY
BMJ Medicine 2023cited by 37position: lastdoi
Challenges in Estimating the Effectiveness of COVID-19 Vaccination Using Observational Data
Annals of Internal Medicine 2023cited by 31position: middledoi
Comparative effectiveness of two- and three-dose COVID-19 vaccination schedules involving AZD1222 and BNT162b2 in people with kidney disease: a linked OpenSAFELY and UK Renal Registry cohort study
The Lancet Regional Health - Europe 2023cited by 28position: middledoi
Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk patients during Omicron waves: observational cohort study using the OpenSAFELY platform
The Lancet Regional Health - Europe 2023cited by 21position: middledoi
Comparative effectiveness of sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in patients on kidney replacement therapy: observational study using the OpenSAFELY-UKRR and SRR databases
Clinical Kidney Journal 2023cited by 9position: middledoi
Ethnic differences in the indirect effects of the COVID-19 pandemic on clinical monitoring and hospitalisations for non-COVID conditions in England: a population-based, observational cohort study using the OpenSAFELY platform
EClinicalMedicine 2023cited by 6position: middledoi
P105 Mode of hospital rheumatology appointments in people with rheumatoid arthritis: the impact of the pandemic in England
Lara D. Veeken 2023cited by 0position: middledoi
Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records
Nature Communications 2022cited by 558position: middledoi
OpenSAFELY: Representativeness of electronic health record platform OpenSAFELY-TPP data compared to the population of England
Wellcome Open Research 2022cited by 114position: middledoi
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform
The Lancet Rheumatology 2022cited by 108position: firstdoi
Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform
BMJ 2022cited by 95position: middledoi
Impact of first UK COVID-19 lockdown on hospital admissions: Interrupted time series study of 32 million people
EClinicalMedicine 2022cited by 80position: middledoi
Mortality among Care Home Residents in England during the first and second waves of the COVID-19 pandemic: an observational study of 4.3 million adults over the age of 65
The Lancet Regional Health - Europe 2022cited by 77position: middledoi
Overall and cause-specific hospitalisation and death after COVID-19 hospitalisation in England: A cohort study using linked primary care, secondary care, and death registration data in the OpenSAFELY platform
PLoS Medicine 2022cited by 66position: middledoi
Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records
BMJ 2022cited by 62position: middledoi
Safety of COVID-19 vaccination and acute neurological events: A self-controlled case series in England using the OpenSAFELY platform
Vaccine 2022cited by 30position: middledoi
Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY
BMC Medicine 2022cited by 29position: middledoi
Rates of serious clinical outcomes in survivors of hospitalisation with COVID-19 in England: a descriptive cohort study within the OpenSAFELY platform
Wellcome Open Research 2022cited by 22position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Ben Goldacre · Angkor Hospital for Children18 papers (2020–2025)Seb Bacon · Science Oxford15 papers (2020–2025)Amir Mehrkar · University of Oxford15 papers (2020–2025)Laurie A. Tomlinson · Science Oxford12 papers (2021–2025)Helen J Curtis · Angkor Hospital for Children11 papers (2020–2024)William Hulme · Angkor Hospital for Children9 papers (2020–2024)Alex J Walker · Angkor Hospital for Children8 papers (2020–2024)Ian Douglas · London School of Hygiene & Tropical Medicine6 papers (2020–2023)Elizabeth Williamson · University of London6 papers (2020–2024)Chris Bates · Texas Public Policy Foundation6 papers (2020–2024)John Tazare · London School of Hygiene & Tropical Medicine6 papers (2022–2024)Anna Schultze · Brigham and Women's Hospital5 papers (2020–2023)Viyaasan Mahalingasivam · London School of Hygiene & Tropical Medicine5 papers (2023–2024)Bang Zheng · Peking University5 papers (2023–2024)Krishnan Bhaskaran · Centre de recherche en Epidémiologie et Santé des Populations5 papers (2020–2024)Rosalind M. Eggo · London School of Hygiene & Tropical Medicine5 papers (2020–2024)Edward P K Parker · London School of Hygiene & Tropical Medicine5 papers (2023–2024)Sinéad Brophy · Swansea University4 papers (2021–2025)John Parry · London School of Hygiene & Tropical Medicine4 papers (2020–2023)Amelia Green · University of London4 papers (2023–2024)